Suchergebnisse - "Galluzzo, Marco"

PubPharm (91)

11

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

enthalten in: Expert opinion on pharmacotherapy | 2023

von Galluzzo, M. | Vellucci, L. | Marcelli, L. | +3

12

Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab : A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2023

von Gargiulo, L. | Ibba, L. | Malagoli, P. | +21

13

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis : An Expert Delphi Consensus Statement

enthalten in: Journal of clinical medicine | 2023

von Fargnoli, M. | Bardazzi, F. | Bianchi, L. | +29

14

Guselkumab for treatment of moderate-to-severe plaque psoriasis : real-life effectiveness and drug-survival for up to 148 weeks

enthalten in: Expert opinion on biological therapy | 2023

von Galluzzo, M. | Marcelli, L. | Vellucci, L. | +6

15

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2023

von Campione, E. | Lambiase, S. | Gaeta Shumak, R. | +10

16

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor

enthalten in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2023

von Papi, C. | Granata, G. | Galluzzo, M. | +1

CommentIn: Neurol Sci. 2023 Aug;44(8):2981-2982. - PMID 37041395

17

Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis : 42-Month Results from the SUPREME 2.0 Study

enthalten in: Clinical, cosmetic and investigational dermatology | 2023

von Russo, F. | Galluzzo, M. | Stingeni, L. | +40

18

Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

enthalten in: Expert opinion on biological therapy | 2022

von Galluzzo, M. | Talamonti, M. | Bernardini, N. | +22

19

Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis

enthalten in: Vaccines | 2022

von Morelli, M. | Galluzzo, M. | Scarponi, C. | +6

20

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor

enthalten in: Neurological sciences | 2022

von Papi, C. | Granata, G. | Galluzzo, M. | +1